Abstract: A stabilizer is provided with a restriction ring connected to a torsion portion at a connection portion adjacent to a bush. The restriction ring has a body, a female portion, a male portion, and a welded portion. The female portion has gripping portions with a spacing therebetween decreasing in the direction away from a valley bottom portion. The male portion has a neck portion, an expansion portion, and a contraction portion. The welded portion covers at least the range of the contraction portion and the valley bottom portion and melts in the plate thickness direction from the outer peripheral surface.

Abstract: A stabilizer is provided with a restriction ring connected to a torsion portion at a connection portion adjacent to a bush. The restriction ring has a body, a female portion, a male portion, and a welded portion. The female portion has gripping portions with a spacing therebetween decreasing in the direction away from a valley bottom portion. The male portion has a neck portion, an expansion portion, and a contraction portion. The welded portion covers at least the range of the contraction portion and the valley bottom portion and melts in the plate thickness direction from the outer peripheral surface.

Abstract: A semi-finished product (31) includes a first curved portion on one end of a plate-shaped bridge portion (33), and a second curved portion (37) on the other end of the bridge portion (33). The second curved portion (37) includes at the end a second lock portion (51) to lock with a first lock portion (41). The bridge portion (33) and the inner circumferential surfaces of the first and second curved portions (35, 37) are pressure-contacted and caulked on the outer circumferential surface of the stabilizer bar (11) by first and second dies (61, 62). At least one of the inner circumferential surfaces (31c) of the first and second curved portions (35, 37) and the outer circumferential surface of the stabilizer bar opposed to the inner surfaces (31c) is formed with an anti-slippage portion (38). The inner circumferential surfaces (31c) of the first and second curved portions (35, 37) and the outer circumferential surface of the stabilizer bar (11) have an anti-slippage material (Co) therebetween.

Abstract: A stabilizer bar with rubber bush includes a stabilizer bar (2), and at least one rubber bush (6) adhesively fixed to at least a portion of the stabilizer bar. The stabilizer bar (2) and the rubber bush (6) are adhesively fixed to each other with an adhesive agent layer (3). The adhesive agent layer (3) includes a primer agent layer (4) formed on a surface of the stabilizer bar (2) and having a dry film thickness of 3 ?m or more and 13 ?m or less; and a first top coat agent layer (5) formed on the primer agent layer (4) and having a dry film thickness of 5 ?m or more and less than 13 ?m.

Abstract: A pipe-shaped member of the present invention is a pipe-shaped member (1) which includes a flat plate portion (1h1, 1h2) placed in at least one end portion (1a1) of two end portions of the pipe, formed in a flat plate shape, and including groove-shaped recessed portions (ta1, tb1, tb2) formed in one and another extended surfaces in the flat plate shape. The recessed portions (ta1, tb1, tb2) are formed such that the flat plate portion (1h1, 1h2) has at least a substantially W-shape, in a direction crossing a longitudinal direction of the flat plate portion (1h1, 1h2), and with a depth not reaching a boundary (1ha) between one plate (1h1) and the other plate (1h2) of the flat plate portion (1h1, 1h2).

Abstract: A semi-finished product (31) includes a first curved portion on one end of a plate-shaped bridge portion (33), and a second curved portion (37) on the other end of the bridge portion (33). The second curved portion (37) includes at the end a second lock portion (51) to lock with a first lock portion (41). The bridge portion (33) and the inner circumferential surfaces of the first and second curved portions (35, 37) are pressure-contacted and caulked on the outer circumferential surface of the stabilizer bar (11) by first and second dies (61, 62). At least one of the inner circumferential surfaces (31c) of the first and second curved portions (35, 37) and the outer circumferential surface of the stabilizer bar opposed to the inner surfaces (31c) is formed with an anti-slippage portion (38). The inner circumferential surfaces (31c) of the first and second curved portions (35, 37) and the outer circumferential surface of the stabilizer bar (11) have an anti-slippage material (Co) therebetween.

Abstract: A stabilizer bar with rubber bush includes a stabilizer bar (2), and at least one rubber bush (6) adhesively fixed to at least a portion of the stabilizer bar. The stabilizer bar (2) and the rubber bush (6) are adhesively fixed to each other with an adhesive agent layer (3). The adhesive agent layer (3) includes a primer agent layer (4) formed on a surface of the stabilizer bar (2) and having a dry film thickness of 3 ?m or more and 13 ?m or less; and a first top coat agent layer (5) formed on the primer agent layer (4) and having a dry film thickness of 5 ?m or more and less than 13 ?m.

Abstract: A pipe-shaped member of the present invention is a pipe-shaped member (1) which includes a flat plate portion (1h1, 1h2) placed in at least one end portion (1a1) of two end portions of the pipe, formed in a flat plate shape, and including groove-shaped recessed portions (ta1, tb1, tb2) formed in one and another extended surfaces in the flat plate shape. The recessed portions (ta1, tb1, tb2) are formed such that the flat plate portion (1h1, 1h2) has at least a substantially W-shape, in a direction crossing a longitudinal direction of the flat plate portion (1h1, 1h2), and with a depth not reaching a boundary (1ha) between one plate (1h1) and the other plate (1h2) of the flat plate portion (1h1, 1h2).

Abstract: The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcoholic fatty liver disease toxic fatty liver or the like.

Abstract: The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 represents N or CR1; X2 represents N or CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a halogen atom, etc.) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications, obesity or the like, pharmaceutical compositions comprising the same, and medicinal uses thereof.

Abstract: The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcoholic fatty liver disease toxic fatty liver or the like.

Abstract: The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1, R2 and R3 represent a hydrogen atom or a halogen atom; R4 represents a lower alkyl group or a halo(lower alkyl) group; and R5 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, etc., a pharmaceutically acceptable salt thereof or a prodrug thereof., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

Abstract: The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 and X3 independently represent N or CH; X2 represents N or CR2; X4 represents N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 represent N; R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy(lower alkoxy)-substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A- wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R3 represents a hydrogen a

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

Abstract: The present invention relates to glucopyranosyl-oxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted(lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

Abstract: The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

Abstract: The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

Abstract: The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.